Business
Ascendis Pharma’s 2026 Results Leave Trial Updates Unverified
Ascendis Pharma reported second-quarter 2026 revenue above consensus but EPS below expectations. The available evidence does not verify the trial updates referenced in the report headline or establish whether the stock is fully priced.
